Skip to main content

Table 2 Applied treatment options during disease progression in all patients (n = 35)

From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

 

Therapies prior to initial PRRT

Additional therapies after initial PRRT and prior to salvage PRRT

Additional therapies after salvage PRRT

Surgery

23 (65.7%)

9 (25.7%)

Biotherapy

22 (62.9%)

5 (14.3%)

Local ablative therapy (RFA, TACE, SIRT)a

12 (34.3%)

9 (25.7%)

3 (8.6%)

Chemotherapy

2 (5.7%)

1 (2.9%)

7 (20.0%)

Everolimus

1 (2.9%)

10 (28.6%)

Protein Kinase Inhibitor / Antibodyb

8 (22.9%)

Radiotherapy

2 (5.7%)

3 (8.6%)

1 (2.9%)

Bone targeted therapyc

7 (20.0%)

5 (14.3%)

4 (11.4%)

  1. aRFA Radiofrequency ablation, TACE transarterial chemoembolisation, SIRT selective internal radiotherapy; b including tyrosine kinase inhibitors and bevacizumab, c Denosumab and Bisphosphonates